Johnson & Johnson today announced significant long-term findings from the Phase 3 QUASAR study program, demonstrating that TREMFYA® (guselkumab) delivered sustained rates of clinical remission [Read More…]
The purpose of the duplicate, randomized, double-blind KALOS and LOGOS trials was to examine Breztri as a possible asthma medication.
IMAAVY demonstrated a swift and significant decrease in IgG levels, a primary driver of gMG, in key adult and pediatric trials.
Adult GCA can now be treated with RINVOQ (upadacitinib), the first and only oral Janus Kinase (JAK) inhibitor authorized for this purpose.
The gadget analyzes images using artificial intelligence to achieve a degree of diagnosis accuracy that is not achievable with conventional manual grading techniques.
In more than three decades, the first possible therapy breakthrough for BCG-naïve, high-risk non-muscle invasive bladder cancer has been the combination of BCG and sasanlimab, a subcutaneously administered PD-1 inhibitor.
In contrast to conventional cardiac ablation techniques, PFA therapy targets specific cardiac tissue regions with high-energy electrical pulses that result in irregular heartbeats.
Amgen has made about $5 billion in direct capital investments in the US since the Tax Cuts and Jobs Act of 2017 was passed.
CENTERSTONE is the first worldwide phase III trial that shows how effective an antiviral medication is at slowing the spread of a respiratory virus.
AbbVie declared that they had submitted the Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE) to the United States FDA for the treatment of moderate to severe glabellar lines. [Read More…]
